PharmaTelevision - Living Cell Technologies: New Technologies and Clinical Trials

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Living Cell Technologies: New Technologies and Clinical Trials

Visitors: You are watching a 30 seconds preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks with Dr Paul Tan, CEO of Living Cell Technologies.

Filmed at AusBiotech 2009, they discuss:

• The company’s origins and aims
• Pig islet transplantation to combat diabetes
• Results of Russian and New Zealand clinical trials
• Living Cell Technologies’ issues with clinical trials in Australia
• The company’s search for a clinical service partner

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Living Cell Technologies's origins and aims

Fintan Walton:

Hello and welcome to PharmaTelevision news review here in Melbourne, Australia. On this show I have Paul Tan, who is CEO of a company called Living Cell Technologies. Welcome to the show.

Paul Tan:

Thank you for having us on your program.

Fintan Walton:

Paul, your company is a company that's involved in the area of diabetes in particular transplantation and the technology you've developed is pig-islets and the transplantation of those pig-islets into humans tell me how the company started and what it's specific aims are?

Paul Tan:

The company started with research that was done by Professor Bob Elliott at the University of Auckland and Bob together with David Collinson a business man started this company because David's son had insulin dependent Type I diabetes, so that research has developed over the years into a new treatment for Type I diabetes the aim of which is to control blood glucose and better control of diabetes overall.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Paul Tan

Chief Executive Officer

Dr Paul Tan has been an executive director since 23 February 2007 and was appointed as Chief Executive Officer of the Group on 23 December 2008. Paul joined the company in 2004 as the Managing Director of LCT's New Zealand operations. Prior to this he was Chief Executive Officer of CenTec Ltd and founding Deputy Director and Head of Health Division at Genesis Research & Development Corporation Limited. He has wide experience in all aspects of assessment and selection of products for commercialization, expansion of intellectual property, product development and managing critical paths, timelines and establishing and managing international partnerships. He has been a research fellow, associate professor in immunology and a physician rheumatologist. He is on the NZBio National Advisory Council and Committee of the NZBio Auckland.

Living Cell Technologies

Living Cell Technologies: Developing cell-based therapies for type 1 diabetes and neurological disorders. LCT is a New Zealand based biotechnology company focused on developing living cell products for the treatment of diabetes, neurological disease and haemophilia. We have collaborations in Melbourne, Sydney, Auckland, Germany, Italy, Russia and the US.